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High-Intensity Focused Ultrasound
Therapy: an Overview for Radiologists
High-intensity focused ultrasound therapy is a novel, emerging, therapeutic
modality that uses ultrasound waves, propagated through tissue media, as carri-
ers of energy. This completely non-invasive technology has great potential for
tumor ablation as well as hemostasis, thrombolysis and targeted drug/gene deliv-
ery. However, the application of this technology still has many drawbacks. It is
expected that current obstacles to implementation will be resolved in the near
future. In this review, we provide an overview of high-intensity focused ultrasound
therapy from the basic physics to recent clinical studies with an interventional
radiologist’s perspective for the purpose of improving the general understanding
of this cutting-edge technology as well as speculating on future developments.
ocusing the sunrays onto a small spot with a magnifying glass to start a
fire is a childhood experiment that many of us tried. High-intensity
focused ultrasound (HIFU) therapy is a technology with similar principles
using ultrasound (US) instead of sunrays. HIFU therapy can transport energy in the
form of US waves through a media of intervening tissues to specific target points of
body organs, and hence, increase the temperature or bring about other biological
interactions in an absolutely non-invasive manner. No significant negative biological
effects on the intervening tissue occurs as long as that the ultrasonic energy is
appropriately located and focused. Because of its non-invasive nature, this technology
has attracted the attention of clinicians, investigators and companies from around the
world as an innovative, interventional tool that might provide virtually complication-
free therapy.
The use of US for therapy predates its application in diagnosis. The biological effects
of HIFU were recognized in 1927 (1). Since the 1930s, unfocused, usually low-
intensity US has been adopted for physiotherapy (2). In 1942, Lynn et al. (3)
demonstrated that highly localized biological effects could be produced by focusing
US. In the 1950s, focused US was employed for brain therapy through a soft tissue
window by Drs. Fry for the first time (4, 5), and then, clinical application was
attempted for Parkinson’s disease (6). However, this clinical application was overshad-
owed by the development of L-dopa, which was considered very successful at the
time. After a long period of relative inactivity, technological advances within the past
10 or more years have caused a resurgence of this technology in clinical medicine. The
first report on the clinical use of HIFU for prostate cancer was published in 1994 (7),
which was followed by many additional clinical studies on its use on a variety of body
organs.
Although most clinical studies on HIFU therapy have dealt only with thermal
ablations (focused US surgery; FUS) (discussed later), the range of its potential applica-
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Ftions in medical science appears to be much wider when
numerous on-going investigations on hemostasis,
thrombolysis and targeted drug/gene-delivery systems are
considered.
In this review, we provide information encompassing the
basic physics of sound required for understanding this
therapy, biological interactions of US, the mechanisms of
action of HIFU therapy, clinical HIFU devices, methods for
guiding and monitoring therapy, and the results of clinical
studies from the viewpoint of interventional radiologists.
Our goal is to improve the general understanding of the
status of technological development of HIFU therapy as
well as speculate on the future direction of this novel
technology.
Basic Physics of Sound and Ultrasound
Sound is defined as a disturbance of mechanical energy
that propagates through a medium in the form of waves.
As this definition implies, sound can transport energy from
its source to another area as long as a medium is present.
US is a form of sound that has a higher frequency (>
20,000 Hz) than the human ear can detect (20 20,000 Hz;
audible ranges). The important parameters of sound are
summarized in Figure 1.
While other minimally invasive therapies such as
radiofrequency ablation or microwave ablation use an
electrode or antenna to deliver electromagnetic waves,
HIFU therapy makes use of US waves as carriers of
energy, which is propagated through human tissues. US
has been shown to have no detrimental effect on the
human body within the diagnostic ranges used (8, 9).
However, it must be noted that US waves carry energy
that causes biological reactions in various ways (discussed
later) although these are usually minimal. The main
challenge of this technique is to maximize energy-accumu-
lation at the target area in order to induce significant
biological reactions without causing harm to the interven-
ing tissues such as the skin and the tissues surrounding the
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Fig. 1. Important physical parameters of
sound physics and their relations. 
Fig. 2. Basic concept of HIFU-induced tissue change by
hyperthermia. As US waves are focused onto small spot,
acoustic pressure is rapidly elevated near focus where tissue
temperatures are also raised to level that is sufficient for
thermotherapeutic effects, resulting in coagulation necrosis.target area. HIFU therapy has adopted two strategies to
resolve this problem. It uses high energy US waves
generated from numerous sources and focuses them to a
small spot (Fig. 2). 
Sonic intensity (SI) can be defined as a time-average rate
of sonic energy-flow through a unit area (SI unit: W/cm
2).
The sonic intensity is proportional to sonic pressure square
and has a positive correlation with the power and energy
of sound (10). This implies that the higher the sonic
pressure or intensity is, the larger the energy accumulation
at the target area is (Fig. 3). Sonic intensity varies with
space and time, and it is usually expressed as peak or
average intensity, and both quantities can refer to either a
spatial or temporal dimension (e.g. ISP = spatial peak
intensity, ISATA = spatial average, temporal average
intensity) (11, 12). In general, tissue-heating by US absorp-
tion is best predicted by the average intensity and the
activity of acoustic cavitation by peak intensity (12). High-
intensity US generally refers to US with an intensity
(ISATA) higher than 5 W/cm
2. This type of US can transfer
enough energy to cause coagulation necrosis of tissue and
is usually used for ultrasonic surgery. By contrast, low-
intensity US (ISATA = 0.125-3 W/cm
2) causes non-destruc-
tive heating, therefore, it stimulates or accelerates normal
physiological responses to an injury. This range of US is
usually used for physiotherapy (13).
The various methods of focusing US waves have been
another important issue. The simplest and cheapest (often
most accurate) method may be a shelf-focusing, for
instance, a spherically curved US source (transducer). An
US transducer constructed according to this method, has a
beam focus fixed at the position determined from the
geometrical specifications of the transducer. To compen-
sate for its lack of versatility, a flat US transducer with an
interchangeable acoustic lens system was devised. The
acoustic lens enables variation of focusing properties such
as focal length and focal geometry. However, a drawback
of the lens system is that US waves undergo sonic attenua-
tion due to absorption by the lens (14). Recently, a phased-
array US transducer technique was adopted for HIFU
therapy. By sending temporally different sets of electronic
signals to each specific transducer component, this
technique enables beam-steering and focusing, which can
move a focal spot in virtually any direction within
physically allowed ranges. This system is not only more
versatile than other systems but also highly efficient
without any sonic attenuation (15) (Fig. 4). 
Biological Interactions of US
US beyond the diagnostic ranges can bring about various
kinds of reactions when insonated into biological tissue.
The resulting effects include thermal, mechanical, chemical
and optical reactions. Mechanical effects, more specifically,
may consist of acoustic cavitation, radiation force, shear
stress, and acoustic streaming/microstreaming. Among
them, the thermal effect and acoustic cavitation are the
most significant, and their mechanisms of action have been
relatively well-understood (16).
The thermal effect is caused by the absorption of US into
biological tissue. US waves cause vibration or rotation of
molecules or part of macromolecules in the tissue, and this
movement results in frictional heat. Depending on the
temperature and the duration of contact, the tissue may
become more susceptible to chemotherapy or radiotherapy
(> 43 C, 1 hour) or alternatively, protein denaturation
may occur (coagulation necrosis) (56 C, 1 sec) (12, 16, 17)
as shown in Figure 2. Excluding the effects of thermal
transfer, the temperature-elevation of biological tissue by
US (plane wave) absorption is theoretically linearly-
proportional to sonic intensity in the following manner (
T/ t = 2 I/ CP = 0.014 I; T = temperature [ C], t = time
[sec],  = absorption coefficient [ 0.03 Np/cm in tissue-
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Fig. 3. Relationships between sound pressure, power, energy,
and intensity. Sonic intensity, defined as energy passing through
unit area within unit time, is derived from plane wave. As seen in
equation, intensity is proportional to square of acoustic pressure
and is also function of property of medium (density and speed of
sound) through which waves are propagated.like medium at 1 MHz], I = sonic intensity,  = density [
1 g/cm
3 in tissue-like medium], Cp = specific heat [ 4.2
J/g C in tissue-like medium]) (18, 19). Because of this
linearity and predictability, a thermal effect was tradition-
ally preferred to a mechanical effect in the medical applica-
tions of FUS.
Acoustic cavitation, defined as the formation and activity
of a gas- or vapor-filled cavity (bubble) in a medium
exposed to an US field, plays a major role in the mechani-
cal effects and minor roles in the chemical and the optical
effects of US technology. If an US wave, more intense than
a specific threshold, is insonated into biological tissue,
negative pressure representing the rarefaction of an US
wave, may be large enough to draw gas out of the tissue
solution to form a bubble. It is easy to understand the
underlying mechanism if this is compared to the numerous
bubbles formed by vigorous rotation of a motorboat screw.
This bubble either repeats radial oscillations in a resonant
size with the insonated frequency (stable cavitation; non-
inertial cavitation) or oscillates in a similar manner expand-
ing gradually above its resonant size due to net influxes of
vapor into the bubble (rectified diffusion), and finally
disintegrates by a violent and asymmetrical collapse
(unstable cavitation; inertial cavitation) (8, 16) (Table 1).
Acoustic cavitation, particularly inertial cavitation, can
cause a significant degree of mechanical and thermal
effects as well as chemical and optical effects. The thermal
effect caused by acoustic cavitation is larger than that
caused by US absorption alone. Mechanical and thermal
effects by acoustic cavitation are generally known to be
complex, unpredictable, and, sometimes, detrimental. The
threshold of acoustic cavitation depends on (negative)
pressure amplitude and frequency of the sound and the
tissue where cavitation occurs (8, 16, 20).
Radiation force is a force exerted at an interface between
two media or inhomogeneity in a medium due to the
passage of US waves. An acoustic field in fluid may set up
acoustic streaming; the transfer of momentum to liquid, by
the absorption of energy from an acoustic field, causes
acoustic streaming. The fluid velocity caused by acoustic
streaming is spatially non-uniform thereby generating a
velocity gradient in the field. This gradient causes shear
Kim et al.
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Table 1. Qualitative Comparison of Stable (non-Inertial) and Unstable (inertial) Cavitation
Stable (non-inertial) Cavitation Unstable (inertial) Cavitation
Mechanism Large amplitude radial oscillation of resonant- Net influx of vapor into bubble (rectified diffusion) 
sized bubbles at insonified frequency expansion above resonant size  asymmetric & 
violent collapse  disintegration
Mechanical effect Less violent More violent (pressure > 1000 atm)
Thermal effect None / minimal High microscopic temp (1,000 - 20,000 K)
Sonochemistry Not known Free radical formation
Sonoluminescence Not known Emission of light
Fig. 4. Various methods of focusing US
waves: A. Spherically-curved
transducer, B. Flat transducer with
interchangeable lens, C. Phased-array
transducer causing only steering, and D.
Phased-array transducer causing
steering and focusing at same time.
AB
CDstress. Acoustic streaming caused by an oscillating bubble
in a sound field immediately surrounding the bubbles is
specifically referred to as acoustic microstreaming. Shear
stress formed by microstreaming is an important
mechanism underlying many biological reactions (8, 16).
Mechanisms of Action in Various Therapies
Focused Ultrasound Surgery (FUS)
Focused ultrasound surgery is used for local ablation
therapy of various types of tumors using HIFU (ISA = 100
10,000 W/cm
2). The two main mechanisms involved in
FUS are thermal effects by US absorption and mechanical
effects involving thermal effects in part, induced by
acoustic cavitation. The thermal effect by absorption has
been traditionally employed because it is relatively
accurately predictable and thus easy to control. This
enables the therapy to be safe even though thermal
ablation by the conventional method of FUS generally
requires a long surgical time for clinical practice. the effects
of cavitation have proven to have potential in improving
the efficiency of the therapy by enlarging the ablation size
and subsequently reducing the procedure-time for ablation
(21). However, these advantages could be accompanied by
a longer cooling time and a relatively high risk of complica-
tion.
The shape of a classical thermal lesion resembles a cigar,
paralleling the direction of the US propagation, measuring
about 1.5 2 mm in width and about 1.5 2 cm in length
when produced by a typical clinical 1.5 MHz HIFU field as
shown in Figure 5 (12, 22). This single thermal lesion is
extremely small in comparison to the sizes of common
clinical tumors. The individual thermal lesions are stacked
up closely without leaving intervening viable tissue to form
a sufficient ablation zone to cover the tumor itself as well
as the safety margin. The tissue-homogeneity influences
the shapes of the thermal lesion while the tissue-perfusion
may affect its size. The frequency of US is adjusted to
optimize surgical conditions, keeping sonic attenuation low
(advantage of low frequency) as well as making energy
focused sharply enough (advantage of high frequency)
(22). 
The histological changes made by FUS have been investi-
gated. Thermal damage after US absorption has been
described as an “island and moat” in which the “island”
represents an area of complete coagulation necrosis and
complete destruction of the tumor-supplying vessels
whereas the “moat” refers to the surrounding rim-like area
that is 6 10 cells-thick and composed of glycogen-poor
cells ( 2 hours) that usually die within 48 hours. Later,
granulation tissue, fibroblast infiltrates and finally retrac-
tion/scar formation occurs (22, 23). The changes that occur
because of acoustic cavitation are both coagulation
necrosis and mechanical tearing. Mechanical tearing, which
is attributed to tissue boiling as well as the mechanical
effects of acoustic cavitation, manifests as holes or
implosion cysts upon microscopic examination (24). 
Hemostasis
Application of HIFU therapy to hemostasis was primarily
initiated in an attempt to control battlefield injuries on the
spot. High-intensity US (ISA = 500 3,000 W/cm
2) is
usually adopted for hemostasis. Many studies on animal
models have been successful for both solid organ and
vascular injuries (25).
The thermal effect has a major role in hemostasis. The
High-Intensity Focused Ultrasound Therapy
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Fig. 5. Classical thermal lesion formed
by focused US surgery (US absorption
only) on porcine liver specimen.
A. Cigar-shaped thermal lesion is formed
at focal zone of US wave pathway (two
overlaid triangles) following HIFU single
exposure. 
B. Final thermal lesion after stacking
each single lesion. Single lesions are
much smaller than clinically common
tumors and therefore each thermal lesion
should be stacked compactly without
leaving intervening viable tissue. This
lesion can cover entire pathological
lesion as well as has very sharp margin
that could be controlled easily.proposed mechanisms of its action are as follows.
Structural deformation of the parenchyma of a solid organ
due to high temperature induces a collapse of small vessels
and sinusoids or sinusoid-like structures. Heat also causes
coagulation of the adventitia of vessels, and subsequently,
fibrin-plug formation. The mechanical effect of acoustic
cavitation also appears to play a minor role in hemostasis.
Microstreaming induces very fine structural disruption of
the parenchyma to form a tissue homogenate that acts as a
seal and induces the release of coagulation factors (25). No
statistically significant hemolysis or changes in the number
of white blood cells and platelets have been observed
when blood is exposed to HIFU with intensities up to 2000
W/cm
2 (26). 
Thrombolysis
US can play a significant role in thrombolysis. US
with/without a thrombolytic agent has been shown to be
effective in enhancing thrombolysis. Thrombolysis is
achieved with low intensity US (ISA = 0.5 1 W/cm
2) and is
known to be associated with non-thermal mechanisms (27,
28). Microstreaming by acoustic cavitation produces a
strong mechanical force around the cell membranes that
causes the pores or channels to open. This increases the
bioavailability of thrombolytic agents on the surface of a
thrombus. The radiation force of the US itself could push
the drug to the lesion (“push effect”). The direct mechani-
cal effect with/without microstreaming could cause
alterations to the fibrin mesh. These effects, described
above, are believed to work synergistically to cause
thrombolysis (29).
There are two methods of delivering US to thrombosed
vessels. One is an extracorporeal approach. This is non-
invasive, but requires higher US energy for compensating
attenuation through an intervening tissue; in addition, it
may have the potential risks of complications and
treatment-failure due to the intervening tissues. Clinical
trials using the extracorporeal low frequency US (as in
transcranial Doppler US) for brain ischemia with the
assistance of a tissue plasminogen activator have turned
out to be successful (30). The other method is via a
miniaturized transducer, at the tip of an arterial catheter,
from which a thrombolytic drug is released. This system is
minimally invasive and commercially available (EKOS
EndoWave Pheripheral Infusion System, EKOS
NeuroWave Catheter; EKOS Co., Bothell, WA).
Targeted Drug/Gene-Delivery
Although US-assisted thrombolysis was discussed
separately, it is a specific type of targeted drug-delivery
system. US-assisted targeted drug-delivery and gene
therapy share a common mechanism where microbubbles
play a critical role. Microbubbles are the vehicles used for
drug or plasmid DNA (deoxyribonucleic acid)-delivery
either in an encapsulated or an attached form. When these
specially manipulated microbubbles pass through blood
vessels, US (ISA = 0.5 1 W/cm
2) is insonated selectively to
the target area to which the therapeutic agents should be
delivered. The US waves rupture the microbubbles, from
which drugs/genes are released. Furthermore the
microbubbles act as cavitation nuclei, thereby allowing the
acoustic cavitation to take place more easily and on a
greater scale. Violent microstreaming formed by the
rupture of the microbubbles enhances the uptake of
drugs/genes into the cells by sonoporation (a transient
alteration of cell membrane structures due to mechanical
Kim et al.
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Fig. 6. Schematic drawing of US-induced
gene therapy. When plasmid DNA-
containing microbubbles are passed
through blood vessels adjacent to
diseased cells, insonated US waves
rupture microbubbles and release
plasmid DNA. Released DNA penetrates
into cell through membranes by means
of sonoporation.force of US) as well as the “push effect” (Fig. 6) (29, 31,
32). One of the problems of conventional gene therapy,
using viral vectors for gene delivery, is the unwanted
adverse effects of systemic immune responses. US-
enhanced gene therapy can prevent this problem. By
targeting delivery only to the diseased area, it can increase
the concentration of therapeutic agents at a focused area of
disease and lower the probability of systemic complications
(32).
There are two specialized forms of US-enhanced drug
delivery. Sonopheresis is one method, which involves the
US-enhanced penetration of pharmacologically-active
agents through the skin or other anatomical barriers. It is
mediated by acoustic cavitation and microstreaming, which
renders the stratum corneum of the skin temporarily
permeable. This method has had a great clinical impact on
the dermal administration of insulin to diabetics. The
second method is sonodynamic therapy, which makes use
of US to activate photosensitive or sonosensitive drugs.
The exact mechanism is unknown, but the sonolumines-
cence phenomenon resulting from acoustic cavitation is
believed to be involved (12, 29).
Transcranial Brain Therapy
Radiologists who are accustomed to diagnostic US within
the frequency range of 3 12 MHz may harbor the miscon-
ception that US cannot pass through bony structures. Bone
significantly absorbs and reflects US waves because it has
an attenuation coefficient, therefore, it has an acoustic
impedance much higher than those of the surrounding soft
tissues. Some percentages of incident US, even if very
small, may be transmitted through bone if its wavelength is
larger than the thickness of bone, for instance, frequencies
lower than 1 MHz in the case of the skull. This results in
very poor efficiency of energy transfer and excessive
heating of the skull in transcranial US therapy. Another
problem of the transcranial US therapy is the severe
aberration of US waves. This is due to an irregularity of
the skull-thickness and a high speed of sound in the bone
resulting in the defocusing of US beams. To overcome this
low-efficiency problem, a transducer with a large number
of high-energy sources is currently being used. To lower
the skull temperature, investigators have adopted an
external cooling system that circulates chilled water
around the scalp. The active area is maximized by
adopting a hemispheric design, referred to as a piezoelec-
tric component arrangement, to distribute the heat as
widely as possible. To minimize the defocusing problem, a
computerized multi-channel phased-array transducer has
been devised. Directions of the individual beams from the
transducer are controlled by a computer-calculations based
on CT-driven data of the skull thickness for each
corresponding area to focus the US beams to a small
sharply-margined area (15, 33) (Fig. 7). A 512-channel
transducer and driving system have been developed and
tested for the normal brain in vivo (34).
Focused US has also been shown to have the ability to
induce selective opening of the blood brain barrier (BBB)
without damaging normal neuronal tissue (35). This
enables US-enhanced drug-delivery to specific areas of the
diseased brain. Each application or combination of applica-
tions has had significant clinical implications because the
conventional therapies including surgery have very limited
roles in this field.
Role of Microbubble Agents
Intravenous microbubble agent injection during therapy
enhances the effects of many different therapeutic
responses where acoustic cavitation is known to be
involved. The microbubbles injected act as cavitation
nuclei, playing a role in seeding for cavitation and lowering
the threshold of acoustic cavitation. This eventually
High-Intensity Focused Ultrasound Therapy
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Fig. 7. Strategy of transcranial focused
US therapy.increases the activity of acoustic cavitation (11, 12).
In FUS, microbubbles effectively absorb ultrasonic
energy, resulting in a further enhancement of the tissue
temperature and, under the same settings, a shortening of
the sonication time required for treating the same sized
tumors. These have been studied in in-vivo animal models
(36 38). In cases using this technique clinically, the
operator must be careful of complications caused by an
excessive ablation. US-induced thrombolysis proved in
animal models (39) as well as in stroke patients clinically
(40) makes use of microbubble administration, which
improves the effect of thrombolytic agents. Microbubbles
can also enhance HIFU-induced hemostasis. They are
effective in causing vascular thrombosis with a sub-
therapeutic dose of a thrombogenic agent in sclerotherapy
(41) and can increase the efficiency of US-induced
hemostasis in solid organ injury (42). As noted previously,
the role of microbubble agents employed in targeted
drug/gene-delivery are two-fold: as a vehicle for therapeu-
tic agents and a cause of sonoporation, associated with the
increased activity of acoustic cavitation (29, 31).
Transcranial FUS of the brain and opening of the BBB are
reported to be enhanced by the simultaneous administra-
tion of microbubbles in animal experiments (43, 44).
Clinical Devices in Use
Since the 1990s, several commercial companies have
developed different forms of clinical HIFU devices, which
are now in the initial stages of their clinical applications.
Generally, the devices are divided into transrectal and
extracorporeal types according to their energy-delivery
routes, and are also classified into US- and MR (magnetic
resonance)-assisted devices according to their guiding and
monitoring methods. Transrectal devices are exclusively
used for the treatment of prostate pathology. There are
two widely used clinical devices manufactured by
companies in France (Ablatherm HIFU system; EDAP,
Vaulx-en-Velin) and the United States (Sonablate 500
system; Focus Surgery, Inc., Indianapolis, IN). Both
systems are guided and monitored by US imaging modali-
ties. 
Extracorporeal devices are relatively more versatile in
application than transrectal. They can be used for benign
or malignant pathology of the uterus, breast, liver, kidney,
pancreas, thyroid, testis, extremities, and other organs
where US can be delivered through an external surface of
the human body. Clinically available extracorporeal HIFU
devices have been developed by several companies in
China (HAIFU System; Chongqing HIFU Technology, Co.,
Ltd., Chongqing, HIFU Tumor Therapy System; China
Medical Technologies, Inc., Beijing, CZ901 HIFU System;
Mianyang Sonic Electronic, Sichuan) and Israel (Exablate
2000; InSightec, Haifa). Devices from China are US-
assisted and those from Israel are MR-assisted. All Chinese
devices utilize one or two single-element therapeutic
transducers with an imaging transducer incorporated in
their center. The transducers are spherically-curved so as
to focus US waves to their geometrical focus and the area
is mechanically manipulated in order to aim the US waves
to the target spot. It has to be noted that the geometrical
focus does not always coincide with the real beam focus at
which the US intensity has its maximum. On the other
hand, the MR-assisted device from Israel uses a phased-
array transducer with approximately 200 elements that
enables electronic manipulation of a focal zone within
specific ranges. This range of focusing is complemented by
the piezoelectric servo-motor system that also enables
mechanical manipulation of the transducer.
Guiding/Monitoring of Therapy
The hyperechoic changes on B-mode US images do not
actually depict a temperature elevation but reflects either
the activity of acoustic cavitation or tissue boiling (45, 46).
Therefore, there might be a possible mismatch in the
locations between the hyperechoic changes and the real
coagulation necrosis. In order to monitor the HIFU lesion
directly and accurately, research on US thermometry are
underway. The techniques employed may include changes
in the speed of sound with temperatures of a medium (47)
and US tissue elasticity imaging technique (48). Guiding
and monitoring by US are relatively economical,
completely real-time and can simulate HIFU beam
propagation precisely because diagnostic and therapeutic
US waves share a common pathway. However, the
drawbacks include a relatively poor tissue-contrast, a
limited field of view and a progressive deterioration of
image quality as the treatment continues (17).
In contrast to US images, MR imaging modality provides
excellent tissue-contrast and is not limited in terms of the
field of view. MR can quantify changes in temperature and
thermal dose (calculated value of equivalent time at a
reference temperature of 43 ) of the treated tissue
directly. MR thermometry makes use of the phenomenon
of temperature sensitivity of the water proton resonance
frequency (PRF) shift (49). A shift in the PRF is linearly
related to temperature and can be mapped rapidly with
standard MR imaging sequences using phase differences.
However, the conventional MR thermometry is insensitive
to temperature changes in fat and is susceptible to motion
artifacts including tissue-swelling due to the need for image
Kim et al.
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Results of Clinical Studies
The clinical uses of HIFU therapy have been increasingly
concentrated on treating tumors. The accessibility of US
beams to the target organ is the most important determi-
nant of whether or not HIFU therapy can be applied. 
Prostate cancer has the longest history of clinical use of
HIFU, therefore, many clinical studies have been
performed on it. All of the clinical studies have been
carried out with transrectal US-assisted equipment. FUS
for early-stage, localized prostate cancer has been
comparable to surgery in terms of local control, disease-
free survival, and complication rates. The cumulative 5-
year disease-free survival rates range from 68 78% (50
52). However, prospective randomized controlled trials
have not been performed to date. FUS has also proven to
be effective in the control of recurrent prostate cancer after
an external beam radiation therapy (53). 
The uterus provides a good target for FUS treatment
because it is static and located close to the abdominal wall.
Most clinical studies on uterine leiomyoma have been done
with MR-assisted HIFU devices. It is the only disease entity
that is approved by the FDA for treatment using this
device at the time of writing this manuscript. FUS has been
shown to be effective in controlling symptomatic uterine
leiomyomas. Targeted symptom reduction rates have been
reported to be 71% at six months and 51% at 12 months
(54). However, the volume reduction rate of the tumors
was not satisfactory (13.5% at 6 months) (55).
Neoadjuvant use of GnRH (gonadotropin releasing
hormone) turned out to improve both the symptom control
rate (83% at 6 months, 89% at 12 months) and the
volume reduction rate (21% at 6 months, 37% at 12
months) (56). 
The breast is also a superficial and static organ.
However, because of the difficulties in treating the axillary
lymph nodes, the clinical application of HIFU therapy for
breast cancer has been limited. The feasibility as a first line
therapy has not been studied to date; only its local control
rate has been evaluated (the local tumor progression rate
9.1%) (57, 58). 
The liver, especially the right lobe, is not a suitable organ
for the application of FUS because of the large respiratory
excursions and the sonic shadowing caused by the ribs.
Therefore, most clinical studies have been carried out on
palliative applications rather than for curative purposes
(59 61). FUS has proven to be effective in lengthening the
survival of patients with advanced hepatocellular carcino-
mas in combination with transcatheter arterial chemoem-
bolization (61). Liver cancer is a great prey of interven-
tional oncologists. In order to overcome these problems,
techniques utilizing FUS, which forms an excellent non-
invasive weapon, are being investigated by researchers and
manufacturers.
Pancreatic cancer is also a promising field for the pallia-
tive application of FUS. In one study, 100% of the patients
experienced resolution of back-pain after the treatment
(62). The effects of FUS on primary and metastatic renal
cancers (63), malignant bone tumors (64), soft tissue
sarcomas (64), testicular tumors (65), and brain tumors
(66) also have been evaluated and most have found
application for palliative purposes useful.
Limitations and Future Works
Major differences of HIFU therapy from other interven-
tional therapeutic modalities are its complete non-invasive-
ness and sharp, tailorable treatment margins, which may
lead to treatments with very low complication rates.
However, several complications have been known to occur
after HIFU therapy. These are mostly due to high-energy
US waves reflected on gas or bony structures (54, 67).
Skin-burn can be caused by poor acoustic coupling
between the skin and the therapeutic window (e.g. poor
shaving) or a previous operation scar. In cases of liver
treatment, reflected US waves on ribs can induce overlying
soft tissue damage including the skin. Gas-containing
bowel loops act in the same manner and can cause thermal
injury of the bowel wall. Sciatic nerve injury was also
reported after HIFU therapy for uterine leimyoma. This
complication is deemed to be caused either directly by
high-energy US waves that pass the focal therapeutic zone
or indirectly by elevated temperatures of the pelvic bone.
If the focal zone is located superficially as in case of breast
cancer, direct thermal injury of overlying skin can occur
(58). Likewise, internal organs just anterior or posterior to
the focal zone could be injured. 
In addition to these complications, HIFU therapy at the
time of writing this manuscript, has displayed several other
limitations, which are hampering the effective use of this
modality in clinical practice. These include a long
procedure time, difficulty in targeting and monitoring
moving organs, sonic shadowing by bones or gas in
bowels, and the relatively high cost of this technique in
relation to its effectiveness and limitations. However,
recent technological advances are expected to resolve
these problems. One example is the new MR-assisted HIFU
device under development, which adopts the technique of
an automatic on-line, spatiotemporal temperature control
using a multispiral trajectory of the focal point and propor-
tional, integral and derivative principles (68). This system
High-Intensity Focused Ultrasound Therapy
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stably under real-time thermal monitoring even in moving
organs than the existing devices (69). 
Summaries and Conclusion
HIFU therapy has great potential in the field of interven-
tional oncology considering its non-invasiveness and sharp
treatment margins leading to treatments with very low
complication rates. In addition, uses of this technology in
combination with other therapeutic and diagnostic modali-
ties, such as targeted drug/gene-delivery, robotic surgery,
and molecular imaging, can be anticipated and has a more
revolutionary clinical impact. 
It may be too early to predict the future of HIFU
therapy. However, there is no doubt that clinical HIFU
therapy, at this point in time, is still in its infancy.
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